image
Healthcare - Medical - Devices - NYSE - US
$ 74.88
3.05 %
$ 2.21 B
Market Cap
57.5
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one INSP stock under the worst case scenario is HIDDEN Compared to the current market price of 74.9 USD, Inspire Medical Systems, Inc. is HIDDEN

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one INSP stock under the base case scenario is HIDDEN Compared to the current market price of 74.9 USD, Inspire Medical Systems, Inc. is HIDDEN

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one INSP stock under the best case scenario is HIDDEN Compared to the current market price of 74.9 USD, Inspire Medical Systems, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INSP

image
$200.0$200.0$180.0$180.0$160.0$160.0$140.0$140.0$120.0$120.0$100.0$100.0$80.0$80.0$60.0$60.015 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 JulAug '25Aug '25
FINANCIALS
803 M REVENUE
28.49%
36.1 M OPERATING INCOME
189.60%
53.5 M NET INCOME
352.96%
130 M OPERATING CASH FLOW
428.32%
-113 M INVESTING CASH FLOW
61.63%
-52.4 M FINANCING CASH FLOW
-375.58%
217 M REVENUE
7.83%
-3.32 M OPERATING INCOME
-123.30%
-3.59 M NET INCOME
-120.05%
2.68 M OPERATING CASH FLOW
140.04%
46.6 M INVESTING CASH FLOW
3098.20%
3.7 M FINANCING CASH FLOW
104.21%
Balance Sheet Inspire Medical Systems, Inc.
image
Current Assets 631 M
Cash & Short-Term Investments 446 M
Receivables 93.1 M
Other Current Assets 92.2 M
Non-Current Assets 178 M
Long-Term Investments 71 M
PP&E 95.2 M
Other Non-Current Assets 11.3 M
55.12 %11.51 %11.40 %8.78 %11.78 %Total Assets$808.4m
Current Liabilities 88.5 M
Accounts Payable 38.7 M
Short-Term Debt 1.75 M
Other Current Liabilities 48.1 M
Non-Current Liabilities 30.2 M
Long-Term Debt 30 M
Other Non-Current Liabilities 148 K
32.60 %40.49 %25.31 %Total Liabilities$118.7m
EFFICIENCY
Earnings Waterfall Inspire Medical Systems, Inc.
image
Revenue 803 M
Cost Of Revenue 123 M
Gross Profit 680 M
Operating Expenses 644 M
Operating Income 36.1 M
Other Expenses -17.4 M
Net Income 53.5 M
900m900m800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00803m(123m)680m(644m)36m17m54mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
84.68% GROSS MARGIN
84.68%
4.49% OPERATING MARGIN
4.49%
6.67% NET MARGIN
6.67%
7.76% ROE
7.76%
6.62% ROA
6.62%
4.58% ROIC
4.58%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Inspire Medical Systems, Inc.
image
100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 53.5 M
Depreciation & Amortization 6.55 M
Capital Expenditures -39.1 M
Stock-Based Compensation 116 M
Change in Working Capital -37.7 M
Others 2.41 M
Free Cash Flow 91.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Inspire Medical Systems, Inc.
image
Wall Street analysts predict an average 1-year price target for INSP of $233 , with forecasts ranging from a low of $200 to a high of $260 .
INSP Lowest Price Target Wall Street Target
200 USD 167.09%
INSP Average Price Target Wall Street Target
233 USD 211.70%
INSP Highest Price Target Wall Street Target
260 USD 247.22%
Price
Max Price Target
Min Price Target
Average Price Target
26026024024022022020020018018016016014014012012010010080806060Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Inspire Medical Systems, Inc.
image
Sold
0-3 MONTHS
259 K USD 1
3-6 MONTHS
6.01 M USD 3
6-9 MONTHS
1.7 M USD 1
9-12 MONTHS
5.16 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
INVESTOR ALERT: Investigation of Inspire Medical Systems, Inc. (INSP) Announced by Holzer & Holzer, LLC ATLANTA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Inspire Medical Systems, Inc. (“Inspire Medical” or the “Company”) (NYSE: INSP) complied with federal securities laws. On August 4, 2025, Inspire Medical announced second quarter 2025 results and updated its 2025 outlook, stating that “the U.S. commercial launch is progressing slower than expected, and the timeline to complete the full transition to Inspire V has been pushed forward, which will impact financial results for the year.” Following this news, the price of the Company's stock dropped. globenewswire.com - 1 day ago
INSP Stock Plunges Despite Q2 Earnings Beat, Gross Margin Contracts Inspire Medical tops second-quarter 2025 earnings estimates and posts solid revenue growth, but trims 2025 guidance amid margin pressure. zacks.com - 1 day ago
Inspire Medical Systems, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation Block & Leviton LLP is investigating Inspire Medical Systems (NYSE: INSP) for potential securities fraud. Investors who lost money should contact the firm. globenewswire.com - 1 day ago
Inspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On Guidance Inspire Medical Systems crashed Tuesday after the maker of implantable sleep apnea devices called out GLP-1 drugs for weighing on sales. investors.com - 1 day ago
Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday. benzinga.com - 1 day ago
Inspire Medical (INSP) Q2 Revenue Up 11% Inspire Medical (INSP) Q2 Revenue Up 11% fool.com - 1 day ago
Inspire Medical Systems, Inc. (INSP) Q2 2025 Earnings Call Transcript Inspire Medical Systems, Inc. (NYSE:INSP ) Q2 2025 Earnings Conference Call August 4, 2025 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Richard J. Buchholz - Chief Financial Officer Timothy P. seekingalpha.com - 1 day ago
Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics The headline numbers for Inspire (INSP) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 day ago
Inspire Medical Systems (INSP) Q2 Earnings and Revenues Surpass Estimates Inspire Medical Systems (INSP) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.32 per share a year ago. zacks.com - 2 days ago
Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2025. globenewswire.com - 2 days ago
Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy? Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 week ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. zacks.com - 3 weeks ago
8. Profile Summary

Inspire Medical Systems, Inc. INSP

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 2.21 B
Dividend Yield 0.00%
Description Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Contact 5500 Wayzata Boulevard, Golden Valley, MN, 55416 https://www.inspiresleep.com
IPO Date May 3, 2018
Employees 1246
Officers Mr. Randall A. Ban EVice President of Patient Access &Therapy Development Mr. Ivan Lubogo SVice President of Strategic Sales Mr. Carlton W. Weatherby Chief Strategy and Growth Officer Ms. Melissa J. Mann Chief People Officer Mr. Andreas Henke Executive Vice President & MD of Europe Mr. Richard J. Buchholz Chief Financial Officer Ms. Ezgi Yagci Vice President of Investor Relations Mr. John C. Rondoni Chief Product & Innovation Officer Mr. Timothy P. Herbert Founder, Chairman, Chief Executive Officer & President Mr. Bryan K. Phillips J.D. Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary